Abstract
By the year 2000 it is estimated that more than 20 million people worldwide will be infected with HIV. Despite many research-related problems, pharmaceutical companies and academic researchers are channelling their efforts into developing new anti-HIV compounds. As outlined by presentations at AIMECS 95 [AFMC International Medicinal Chemistry Symposium; Tokyo, Japan; September 1995] researchers are concentrating on 2 key enzymes in the life-cycle of HIV, namely reverse transcriptase (RT) and HIV protease.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
